Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This investigational cell therapy, developed by University Hospitals Cleveland Medical Center, utilizes autologous bone marrow-derived mesenchymal stem cells (BM-MSCs) for the treatment of symptomatic intervertebral disc degeneration. The procedure involves harvesting the patient's own bone marrow, expanding the MSCs in culture, and then re-injecting them percutaneously under image guidance directly into the nucleus pulposus of the affected disc. The therapy aims to facilitate disc repair and regeneration, potentially alleviating chronic low back pain in patients who have not responded to conservative treatments.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on autologous bone marrow-derived mesenchymal stem cells (University Hospitals Cleveland Medical Center).